https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-03-10 / Front Oncol 2020;10:254
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-03-10 / Front Oncol 2020;10:2542020-03-10 00:00:002020-08-26 14:24:04Putative Abscopal Effect in Three Patients Treated by Combined Radiotherapy and Modulated Electrohyperthermia
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-03-06 / Cancers (Basel) 2020 Mar;12(3)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-03-06 / Cancers (Basel) 2020 Mar;12(3)2020-03-06 00:00:002020-03-06 00:00:00Combined wIRA-Hyperthermia and Hypofractionated Re-Irradiation in the Treatment of Locally Recurrent Breast Cancer: Evaluation of Therapeutic Outcome Based on a Novel Size Classification
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-03-06 / Biomedicines 2020 Mar;8(3)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-03-06 / Biomedicines 2020 Mar;8(3)2020-03-06 00:00:002021-11-15 17:52:40New Insights into Mechanisms of Long-term Protective Anti-tumor Immunity Induced by Cancer Vaccines Modified by Virus Infection
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-03-05 / Cancers (Basel) 2020 Mar;12(3)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-03-05 / Cancers (Basel) 2020 Mar;12(3)2020-03-05 00:00:002020-08-26 13:47:31Dendritic Cells in Anticancer Vaccination: Rationale for Ex Vivo Loading or In Vivo Targeting
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-03-04 / Biomed. Pharmacother. 2020 Jun;126:110046
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-03-04 / Biomed. Pharmacother. 2020 Jun;126:1100462020-03-04 00:00:002020-03-04 00:00:00Dendritic cell vaccine for the effective immunotherapy of breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-03-03 / Clin Transl Immunology 2020;9(3):e1117
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-03-03 / Clin Transl Immunology 2020;9(3):e11172020-03-03 00:00:002020-03-03 00:00:00Toll-like receptor 7/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-03-01 / J Immunother Cancer 2020 Mar;8(1)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-03-01 / J Immunother Cancer 2020 Mar;8(1)2020-03-01 00:00:002020-03-01 00:00:00T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-03-01 / J Immunother Cancer 2020 03;8(1)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-03-01 / J Immunother Cancer 2020 03;8(1)2020-03-01 00:00:002022-09-29 14:17:36Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
